« Back to Record
Citation APA

Overman, M. J., Hill, A., Sawyer, M. M., Hendlisz, A., Neyns, B., Svrcek, M., Moss, R. R., Ledeine, J. M., Cao, A. Z., Kamble, S., Kopetz, S., Lonardi, S., André, T., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. M., Van Cutsem, E., & McDermott, R. (2018). Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. Journal of clinical oncology, 36(8), 773-779. doi:10.1200/JCO.2017.76.9901


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/269547

Overman, M. J., Hill, A., Sawyer, M. M., Hendlisz, A., Neyns, B., Svrcek, M., Moss, R. R., Ledeine, J. M., Cao, A. Z., Kamble, S., Kopetz, S., Lonardi, S., André, T., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. M., Van Cutsem, E., & McDermott, R. (2018). Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. Journal of clinical oncology, 36(8), 773-779. doi:10.1200/JCO.2017.76.9901